findmyKOL
Clinical trialNCT04726553UnknownEarly phase 1Interventional

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

SponsorOklahoma Medical Research FoundationEnrollment20Systemic Lupus Erythematosus (SLE)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study to examines the impact of anifrolumab on disease activity, immune phenotypes, and development of neutralizing antibodies to quadrivalent influenza vaccine in patients with Systemic Lupus Erythematosus (SLE). 10 patients with moderately to severely active SLE will be treated with anifrolumab in addition to standard of care lupus treatments and 10 will receive only standard of care medications. All will receive influenza vaccine.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Yale University Medical Center

    New Haven, Connecticut, United States

    Fotios Koumpouras, M.D.
    Not, yet, recruiting
  • Piedmont Hospital

    Atlanta, Georgia, United States

    Wambui Machua, M.D.
    Not, yet, recruiting
  • Columbia Unversity Medical Center

    New York, New York, United States

    Anca Askanase, M.D.
    Not, yet, recruiting
  • New York University Medical Center

    New York, New York, United States

    Amit Saxena, M.D.
    Not, yet, recruiting
  • Oklahoma Medical Research Foundation

    Oklahoma City, Oklahoma, United States

    Cristina Arriens, M.D. →
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Anifrolumab →Standard of Care
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Jan 2021
Primary completion
31 Dec 2023
Completion
31 Dec 2024
Last update posted
22 Mar 2023
Registered enrollment
20
Registry id
NCT04726553
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.